Novo's Denecimig Tolerable After Switch From Emicizumab
Novo's denecimig shows tolerability after switching from emicizumab in the FRONTIER5 hemophilia A study, published in Journal of Thrombosis and Haemostasis.
Journal Of Thrombosis And Haemostasis | 19/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy